Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
Key Highlights
- ➤Phase 1b data showed no Parkinson’s motor-symptom progression after 12 months
- ➤Phase 2 rexaceract trial expected to begin in Q1 2027
- ➤Q3 net loss narrowed to $0.07 per share from $0.15
- ➤Cash and equivalents fell to $11.7 million from $20.8 million
- ➤GT-04686 initial therapeutic indication expected in Q4 2026
Expert Statements
Gene Mack, President and CEO of Gain Therapeutics
“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD).”
Gene Mack, President and CEO of Gain Therapeutics
“After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms.”
Gene Mack, President and CEO of Gain Therapeutics
“This, together with previously reported biomarker evidence of target engagement, further validates the disease-modifying hypothesis underpinning our development strategy for rexaceract in PD.”
Gene Mack, President and CEO of Gain Therapeutics
“We continue to believe rexaceract has the potential to shift the treatment paradigm beyond symptom management, and we look forward to achieving additional potential clinical and regulatory milestones throughout the remainder of the year.”
Gene Mack, President and CEO of Gain Therapeutics
“As we approach the start of the Phase 2 clinical trial of rexaceract, which we expect to initiate during Q1 2027 after confirming updates to our trial design during Q4 2026, we plan to select an initial therapeutic indication to advance GT-04686 into the clinic.”
Gene Mack, President and CEO of Gain Therapeutics
“We believe advancing a second allosteric small molecule candidate into clinical development is a milestone that will help position us for our next phase of growth as we build a differentiated GCase-targeting platform with the potential to unlock multiple therapeutic opportunities.”
BETHESDA, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended September 30, 2026, and provided a corporate update.
“The third quarter marked an important period of progress for Gain, highlighted by the presentation of long-term open-label data from the Phase 1b trial of rexaceract in Parkinson’s disease (PD),” said Gene Mack, President and CEO of Gain Therapeutics. “After 12 months of dosing with rexaceract, participants enrolled in the study showed no progression of Parkinson’s disease motor symptoms. This, together with previously reported biomarker evidence of target engagement, further validates the disease-modifying hypothesis underpinning our development strategy for rexaceract in PD. We continue to believe rexaceract has the potential to shift the treatment paradigm beyond symptom management, and we look forward to achieving additional potential clinical and regulatory milestones throughout the remainder of the year.”
Get started
Create a free account to read the full story.